About: Drug repurposing against COVID-19: focus on anticancer agents

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Drug repurposing against COVID-19: focus on anticancer agents Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Drug repurposing against COVID-19: focus on anticancer agents
Creator	Ciliberto, Gennaro Mancini, Rita Paggi, Marco
topic	covid:0a9a8d2f4a4f8bd18662b69100679fc9cbfe95a2#this
Source	Medline; PMC
abstract	BACKGROUND: The very limited time allowed to face the COVID-19 pandemic poses a pressing challenge to find proper therapeutic approaches. However, synthesis and full investigation from preclinical studies to phase III trials of new medications is a time-consuming procedure, and not viable in a global emergency, such as the one we are facing. MAIN BODY: Drug repurposing/repositioning, a strategy effectively employed in cancer treatment, can represent a valid alternative. Most drugs considered for repurposing/repositioning in the therapy of the COVID-19 outbreak are commercially available and their dosage and toxicity in humans is well known, due to years (or even decades) of clinical use. This can allow their fast-track evaluation in phase II–III clinical trials, or even within straightforward compassionate use. Several drugs being re-considered for COVID-19 therapy are or have been used in cancer therapy. Indeed, virus-infected cells are pushed to enhance the synthesis of nucleic acids, protein and lipid synthesis and boost their energy metabolism, in order to comply to the “viral program”. Indeed, the same features are seen in cancer cells, making it likely that drugs interfering with specific cancer cell pathways may be effective as well in defeating viral replication. SHORT CONCLUSION: To our knowledge, cancer drugs potentially suitable for facing SARS-CoV-2 infection have not been carefully reviewed. We present here a comprehensive analysis of available information on potential candidate cancer drugs that can be repurposed for the treatment of COIVD-19.
has issue date	2020-05-12(xsd:dateTime)
bibo:doi	10.1186/s13046-020-01590-2
bibo:pmid	32398164
has license	cc-by
sha1sum (hex)	0a9a8d2f4a4f8bd18662b69100679fc9cbfe95a2
schema:url	https://doi.org/10.1186/s13046-020-01590-2
resource representing a document's title	Drug repurposing against COVID-19: focus on anticancer agents
has PubMed Central identifier	PMC7214852
has PubMed identifier	32398164
schema:publication	J Exp Clin Cancer Res
resource representing a document's body	covid:0a9a8d2f4a4f8bd18662b69100679fc9cbfe95a2#body_text
is http://vocab.deri.ie/void#inDataset of	https://covidontheweb.inria.fr:4443/about/id/http/ns.inria.fr/covid19/0a9a8d2f4a4f8bd18662b69100679fc9cbfe95a2
is schema:about of	named entity 'program' named entity 'therapy' named entity 'represent' named entity 'phase' named entity 'proper' named entity 'repurposing' named entity 'YEARS' named entity 'NUCLEIC ACIDS' named entity 'BACKGROUND' named entity 'PHASE III TRIALS' named entity 'PHASE II' named entity 'BODY' named entity 'PROGRAM' named entity 'VIRAL REPLICATION' named entity 'TRACK' named entity 'EFFECTIVE' named entity 'MAIN' named entity 'COVID-19 PANDEMIC' named entity 'FEATURES' named entity 'CANCER THERAPY' named entity 'TIME-CONSUMING' named entity 'EMPLOYED' named entity 'REPRESENT' named entity 'ALLOWED' named entity 'facing' named entity 'This' named entity 'repurposing' named entity 'cancer therapy' named entity 'effective' named entity 'protein' named entity 'preclinical studies' named entity 'cells' named entity 'Conclusion' named entity 'COVID-19' named entity 'nucleic acids' named entity 'Drug repurposing' named entity 'fast-track' named entity 'COVID-19 outbreak' named entity 'phase III trials' named entity 'preclinical studies' named entity 'cancer drugs' named entity 'clinical trials' named entity 'COVID-19' named entity 'Drug repurposing' named entity 'temsirolimus' named entity 'lopinavir' named entity 'long-term' named entity 'rapamycin' named entity 'remdesivir' named entity 'infection' named entity 'causative agent' named entity 'cytotoxic T lymphocytes' named entity 'metabolic' named entity 'life-threatening' named entity 'de-escalating' named entity 'SARS-CoV-2' named entity 'COVID-19' named entity 'catabolic' named entity 'anticancer drugs' named entity 'BCG' named entity 'BCG' named entity 'rhesus macaque' named entity 'organ' named entity 'SARS-CoV-2' named entity 'chemotherapy' named entity 'mTOR' named entity 'iatrogenic' named entity 'cytokine release syndrome' named entity 'viral replication' named entity 'lopinavir' named entity 'ridaforolimus' named entity 'COVID' named entity 'HCV' named entity 'physiological' named entity 'sialic acid' named entity 'immune response' named entity 'cancer cells'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software